A Placebo-controlled, Preliminary Evaluation of Safety, Tolerability, and Efficacy of Ascending Doses of XT-150 for the Treatment of Osteoarthritic Pain
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 20 Mar 2018
At a glance
- Drugs XT-150 (Primary)
- Indications Osteoarthritis
- Focus Adverse reactions
- Sponsors Xalud Therapeutics
- 13 Mar 2018 Treatment arm chaged from 3 to 4 and study design include randomization, endpoint timeframe changed from 30 days to 180 days.
- 05 Feb 2018 Planned number of patients changed from 16 to 24.
- 05 Feb 2018 Planned primary completion date changed from 30 Aug 2018 to 30 Sep 2018.